Showing results (621-630 of 672) with videos related to

Sort By:
Pageof 68
The Journal of Infectious Diseases|November 17, 2006
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby, R Pat Bucy, Donna Mildvan, et al.
International Journal of Cancer|January 3, 2013
The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrenceChuanbo Zhang, Bhaskar V Kallakury, Jeffrey S Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2001
ANX7, a candidate tumor suppressor gene for prostate cancerM Srivastava, L Bubendorf, V Srikantan, et al.
The Journal of Infectious Diseases|October 3, 2017
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral TherapyDavid M Asmuth, Corbin G Thompson, Tae-Wook Chun, et al.
Archives of Internal Medicine|March 29, 2007
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, et al.
Molecular & Cellular Proteomics : MCP|August 23, 2005
Pooled ORF expression technology (POET): using proteomics to screen pools of open reading frames for protein expressionWilliam K Gillette, Dominic Esposito, Peter H Frank, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1997
A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV diseaseD H Shepp, C Ramirez-Ronda, L Dall, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix, Ann C Collier, Michael M Lederman, et al.
The American Journal of Cardiology|October 25, 2016
Comparison of Ambulatory, High-Dose, Intravenous Diuretic Therapy to Standard Hospitalization and Diuretic Therapy for Treatment of Acute Decompensated Heart FailureLeo F Buckley, Enrique Seoane-Vazquez, Judy W M Cheng, et al.
Pageof 68